Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study-Reference-Cited by-同舟云学术

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Published:2018-11-08 Issue:3 Volume:9 Page:370-383
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Daver Naval,Garcia-Manero Guillermo,Basu Sreyashi,Boddu Prajwal C.,Alfayez Mansour,Cortes Jorge E.,Konopleva Marina,Ravandi-Kashani Farhad,Jabbour Elias,Kadia Tapan,Nogueras-Gonzalez Graciela M.,Ning Jing^ORCID,Pemmaraju Naveen,DiNardo Courtney D.,Andreeff Michael^ORCID,Pierce Sherry A.,Gordon Tauna,Kornblau Steven M.,Flores Wilmer,Alhamal Zainab,Bueso-Ramos Carlos,Jorgensen Jeffrey L.,Patel Keyur P.,Blando Jorge,Allison James P.^ORCID,Sharma Padmanee,Kantarjian Hagop

Funder

MD Anderson Cancer Center

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 418 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy;Acta Histochemica;2024-10

2. CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia;Blood;2024-09-12

3. BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML;Science Translational Medicine;2024-09-11

4. Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia;Experimental Hematology & Oncology;2024-09-06

5. A novel molecular classification based on efferocytosis-related genes for predicting clinical outcome and treatment response in acute myeloid leukemia;Inflammation Research;2024-09-02